Loading
companiesCompany
Travera
Travera exposes a patient's living cancer cells to a broad range of approved drugs, including immunotherapies, and measures within days which ones the cells respond to.
Overview
Travera's Rapid Therapy Guidance evaluates a broad range of FDA-approved drug options against a patient's live tumour cells, measuring single-cell mass changes as a readout of drug response, and reports which options showed activity. Based in Medford, Massachusetts; physician-ordered.
Similar pages
- CompanyFirst Ascent Biomedical
Shares Functional (ex vivo) drug testing and the tag fcct-directory.
- Company2cureX
Shares Functional (ex vivo) drug testing and the tag fcct-directory.
- CompanyCure-First
Shares Functional (ex vivo) drug testing and the tag fcct-directory.
- CompanySageMedic
Shares Functional (ex vivo) drug testing and the tag fcct-directory.
- CompanySpeciCare
Shares Functional (ex vivo) drug testing and the tag fcct-directory.
- CompanyKYAN Technologies
Shares Functional (ex vivo) drug testing and the tag fcct-directory.
- CompanyStoreMyTumor
Shares Functional (ex vivo) drug testing and the tag fcct-directory.
- CompanyCanCertain
Shares Functional (ex vivo) drug testing and the tag fcct-directory.